Delivery Order SPE2DB22D2214-SPE2DB25FS6HB
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,244.58 to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) on November 12, 2025, with a completion date of December 4, 2025. This firm fixed price delivery order was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,874.06 on November 18, 2025, for the supply of Ingrezza 40 mg capsules (30-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 10, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $4,027.70 to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed price contract. The award was issued on September 18, 2025, with an ultimate completion date of October 9, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,874.06 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count units). This competitively awarded, firm fixed-price contract was issued on November 4, 2025, with an ultimate completion date of November 26, 2025. The pharmaceutical product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, for the supply of Ingrezza 60 mg capsules (30-count unit). The contract, valued at $4,049.61 with a firm fixed price structure, was awarded on August 4, 2025, with an ultimate completion date of August 25, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's capability to meet federal procurement requirements in open competition....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,622.18 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count units). This firm fixed-price delivery order, awarded on November 7, 2025, with an ultimate completion date of December 2, 2025, represents a non-set-aside competitive procurement. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules in a 30-count package, valued at $8,055.38. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with an ultimate completion date of November 18, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's primary location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $4,027.70 to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) on September 18, 2025, with an ultimate completion date of October 9, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order valued at $3,676.11 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count) on November 5, 2025, with an ultimate completion date of November 28, 2025. This firm fixed-price delivery order represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed price contract valued at $4,027.70, with an ultimate completion date of August 15, 2025. This non-competitive delivery order was issued on July 25, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award represents a child order under the company's larger...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS6HBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,027.70 to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-unit quantity) under a firm fixed-price contract. This non-set-aside award was issued on August 26, 2025, with an ultimate completion date of September 17, 2025. The product will be performed at the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999.99 million through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that serves military and veteran healthcare systems through the DLA Medical Supply Chain. The company holds extensive federal contract awards for a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. Ingrezza (valbenazine) is a neurological treatment used for involuntary movement disorders, reflecting AmerisourceBergen's established portfolio of specialized pharmaceutical deliveries to support Defense Health Agency and other federal healthcare programs. The SPE2DX umbrella contract provides the flexible contracting vehicle through which AmerisourceBergen supplies pharmaceutical products and medical commodities to support military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 8/26/25 |